Hydrochloride pioglitazone decreases urinary monocyte chemoattractant protein-1 excretion in type 2 diabetics.
OBJECTIVE
To observe the effects of hydrochloride pioglitazone on monocyte chemoattractant protein-1 (MCP-1) excretion in type 2 diabetics and explore its reno-protective mechanism.


METHODS
98 uncontrolled type 2 diabetics with fasting blood glucose (FBG) between 7.0 and 13.0 mmol/L and glycated hemoglobin A1c (HbA1c)> or =7.0% were assigned randomly into group DP (pioglitazone add-on) and group DS (sulfonylureas add-on). Another 49 healthy individuals were chosen as normal controls (group NC). At the basal and 12th week, FBG, HbA1c, urinary MCP-1, albumin (UALB) and creatinine (UCr) were determined.


RESULTS
(1) Compared with group NC, all the parameters mentioned above were significantly increased in diabetic groups. (2) Compared with pre-treatment, FBG, HbA1c and urinary MCP-1/UCr ratio (UMCR) were obviously decreased in both therapy groups; systolic blood pressure (SBP), diastolic blood pressure (DBP) and UALB/UCr ratio (UACR) decreased markedly in group DP (P<0.05 or P<0.01), while slightly in group DS (P>0.05). (3) FBG and HbA1c had no marked difference between group DP and group DS after treatment, however, SBP, DBP, UACR and UMCR in group DP were significantly lower than those in group DS (P<0.05 or P<0.01).


CONCLUSIONS
Pioglitazone can decrease urinary albumin and MCP-1 excretion in type 2 diabetics, which may partly contribute to its reno-protection by inhibiting the inflammation reaction in vivo.
Ye
Shandong
S
Department of Endocrinology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Lujiang Street, Hefei 230001, Anhui Province, China. ysd6464@yahoo.com.cn
Zheng
Mao
M
Hu
Yuanyuan
Y
Wu
Fengzhen
F
Zhao
Lili
L
Chen
Yan
Y
D000328:Adult; D000368:Aged; D018932:Chemokine CCL2 / Q000652:urine*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000473:pathology / Q000652:urine*; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome
D018932:Chemokine CCL2; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000077205:Pioglitazone; D045162:Thiazolidinediones